Drug Profile
HIV gene therapy - Adaptimmune/Cardiff University/University of Pennsylvannia
Alternative Names: SLYNTVATLLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Adaptimmune; Cardiff University; University of Pennsylvania
- Developer Adaptimmune; University of Pennsylvania
- Class Cell therapies; Gene therapies
- Mechanism of Action CD8 positive T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections in USA (IV, Infusion)
- 01 Jan 2014 Adaptimmune completes a phase I trial in HIV infections in USA (NCT00991224)
- 01 Nov 2009 Phase-I clinical trials in HIV infections in USA (IV)